Cryptotanshinone alleviates polycystic ovary syndrome in rats by regulating the HMGB1/TLR4/NF‑κB signaling pathway

Yang,Yijiao; Yang,Ling; Qi,Cao; Hu,Guohua; Wang,Longhui; Sun,Zhuojun; Ni,Xiaorong

doi:10.3892/mmr.2020.11469

Cryptotanshinone alleviates polycystic ovary syndrome in rats by regulating the HMGB1/TLR4/NF‑κB signaling pathway

Authors:
- Yijiao Yang
- Ling Yang
- Cao Qi
- Guohua Hu
- Longhui Wang
- Zhuojun Sun
- Xiaorong Ni
View Affiliations

Affiliations: Department of Gynecology, Shanghai University of Traditional Chinese Medicine, Shanghai Traditional Chinese Medicine Hospital, Shanghai 200071, P.R. China, Department of Chinese and Western Medicine, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China
Published online on: August 28, 2020 https://doi.org/10.3892/mmr.2020.11469
Pages: 3851-3861
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cryptotanshinone (CRY) has been demonstrated to reverse reproductive disorders. However, whether CRY is effective in the treatment of polycystic ovary syndrome (PCOS) remains unknown. The aim of the present study was to evaluate the therapeutic potential of CRY in PCOS. A rat model of PCOS was established by daily injection of human chorionic gonadotropin and insulin for 22 days. Total body weight and ovarian weight, as well as the levels of luteinizing hormone (LH) and the LH to follicle‑stimulating hormone (FSH) ratio (LH/FSH) significantly increased in rats with PCOS, compared with controls. Moreover, the levels of testosterone (T), tumor necrosis factor (TNF)‑α and high‑mobility group box 1 protein (HMGB1) also increased. However, CRY treatment attenuated the increase in body weight, ovarian weight, LH, LH/FSH ratio, T, TNF‑α and HMGB1 levels, compared with the PCOS group. Treatment with CRY also reduced NF‑κB/p65, HMGB1 and toll‑like receptor (TLR)4 mRNA and protein expression levels in the ovarian tissue and granulosa cells, both in vitro and in vivo. Thus, CRY significantly mitigated the changes in body weight, ovary weight, hormone levels and inflammatory factor levels observed in rats with PCOS. Thus, CRY protects against PCOS‑induced damage of ovarian tissue, possibly through a regulatory pathway involving HMGB1, TLR4 and NF‑κB.

View Figures

View References

1	Witchel SF, Recabarren SE, González F, Diamanti-Kandarakis E, Cheang KI, Duleba AJ, Legro RS, Homburg R, Pasquali R, Lobo RA, et al: Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome. Endocrine. 42:526–534. 2012. View Article : Google Scholar : PubMed/NCBI
2	Rojas J, Chávez M, Olivar L, Rojas M, Morillo J, Mejías J, Calvo M and Bermúdez V: Polycystic ovary syndrome, insulin resistance, and obesity: Navigating the pathophysiologic labyrinth. Int J Reprod Med. 2014:7190502014. View Article : Google Scholar : PubMed/NCBI
3	Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, et al: Consensus on women's health aspects of polycystic ovary syndrome (PCOS): The amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group. Fertil Steril. 97:28–38.e25. 2012. View Article : Google Scholar : PubMed/NCBI
4	Yuan H, Zhu G, Wang F, Wang X, Guo H and Shen M: Interaction between common variants of FTO and MC4R is associated with risk of PCOS. Reprod Biol Endocrinol. 13:552015. View Article : Google Scholar : PubMed/NCBI
5	Goodarzi MO, Dumesic DA, Chazenbalk G and Azziz R: Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 7:219–231. 2011. View Article : Google Scholar : PubMed/NCBI
6	Ollila MM, Piltonen T, Puukka K, Ruokonen A, Järvelin MR, Tapanainen JS, Franks S and Morin-Papunen L: Weight gain and dyslipidemia in early adulthood associate with polycystic ovary syndrome: Prospective cohort study. J Clin Endocrinol Metab. 101:739–747. 2016. View Article : Google Scholar : PubMed/NCBI
7	Diamanti-Kandarakis E: Polycystic ovarian syndrome: Pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med. 10:e32008. View Article : Google Scholar : PubMed/NCBI
8	Ni XR, Sun ZJ, Hu GH and Wang RH: High concentration of insulin promotes apoptosis of primary cultured rat ovarian granulosa cells via its increase in extracellular HMGB1. Reprod Sci. 22:271–277. 2015. View Article : Google Scholar : PubMed/NCBI
9	Velásquez E: Chronic complications of polycystic ovary syndrome. Review. Invest Clin. 43:205–213. 2002.(In Spanish). PubMed/NCBI
10	Huang Y, Sun J, Wang X, Tao X, Wang H and Tan W: Asymptomatic chronic gastritis decreases metformin tolerance in patients with type 2 diabetes. J Clin Pharm Ther. 40:461–465. 2015. View Article : Google Scholar : PubMed/NCBI
11	Li XJ, Yu YX, Liu CQ, Zhang W, Zhang HJ, Yan B, Wang LY, Yang SY and Zhang SH: Metformin vs. thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: A meta-analysis. Clin Endocrinol (Oxf). 74:332–339. 2011. View Article : Google Scholar : PubMed/NCBI
12	Cholesterol Treatment Trialists' (CTT) Collaboration, ; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, et al: Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 376:1670–1681. 2010. View Article : Google Scholar : PubMed/NCBI
13	Ji XY, Tan BK and Zhu YZ: Salvia miltiorrhiza and ischemic diseases. Acta Pharmacol Sin. 21:1089–1094. 2000.PubMed/NCBI
14	Wang X, Morris-Natschke SL and Lee KH: New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med Res Rev. 27:133–148. 2007. View Article : Google Scholar : PubMed/NCBI
15	Yu J, Zhai D, Hao L, Zhang D, Bai L, Cai Z and Yu C: Cryptotanshinone reverses reproductive and metabolic disturbances in PCOS model rats via regulating the expression of CYP17 and AR. Evid Based Complement Alternat Med. 2014:6707432014. View Article : Google Scholar : PubMed/NCBI
16	Ong M, Peng J, Jin X and Qu X: Chinese herbal medicine for the optimal management of polycystic ovary syndrome. Am J Chin Med. 45:405–422. 2017. View Article : Google Scholar : PubMed/NCBI
17	Huang Y, Li W, Wang CC, Wu X and Zheng J: Cryptotanshinone reverses ovarian insulin resistance in mice through activation of insulin signaling and the regulation of glucose transporters and hormone synthesizing enzymes. Fertil Steril. 102:589–596.e584. 2014. View Article : Google Scholar : PubMed/NCBI
18	Jiang B, Xue M, Xu D, Song Y and Zhu S: Upregulation of microRNA-204 improves insulin resistance of polycystic ovarian syndrome via inhibition of HMGB1 and the inactivation of the TLR4/NF-κB pathway. Cell Cycle. 19:697–710. 2020. View Article : Google Scholar : PubMed/NCBI
19	Yang X, Zhang Y, Wu X, Bae CS, Hou L, Kuang H, Wang Y and Stener-Victorin E: Cryptotanshinone reverses reproductive and metabolic disturbances in prenatally androgenized rats via regulation of ovarian signaling mechanisms and androgen synthesis. Am J Physiol Regul Integr Comp Physiol. 300:R869–R875. 2011. View Article : Google Scholar : PubMed/NCBI
20	Poretsky L, Clemons J and Bogovich K: Hyperinsulinemia and human chorionic gonadotropin synergistically promote the growth of ovarian follicular cysts in rats. Metabolism. 41:903–910. 1992. View Article : Google Scholar : PubMed/NCBI
21	Ngo HT, Hetland RB, Sabaredzovic A, Haug LS and Steffensen IL: In utero exposure to perfluorooctanoate (PFOA) or perfluorooctane sulfonate (PFOS) did not increase body weight or intestinal tumorigenesis in multiple intestinal neoplasia (Min/+) mice. Environ Res. 132:251–263. 2014. View Article : Google Scholar : PubMed/NCBI
22	Mangano C, Scarano A, Perrotti V, Iezzi G and Piattelli A: Maxillary sinus augmentation with a porous synthetic hydroxyapatite and bovine-derived hydroxyapatite: A comparative clinical and histologic study. Int J Oral Maxillofac Implants. 22:980–986. 2007.PubMed/NCBI
23	deMoura MD, Chamoun D, Resnick CE and Adashi EY: Insulin-like growth factor (IGF)-I stimulates IGF-I and type 1 IGF receptor expression in cultured rat granulosa cells: Autocrine regulation of the intrafollicular IGF-I system. Endocrine. 13:103–110. 2000. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	March WA, Moore VM, Willson KJ, Phillips DIW, Norman RJ and Davies MJ: The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 25:544–551. 2010. View Article : Google Scholar : PubMed/NCBI
26	Azziz R, Marin C, Hoq L, Badamgarav E and Song P: Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab. 90:4650–4658. 2005. View Article : Google Scholar : PubMed/NCBI
27	Barthelmess EK and Naz RK: Polycystic ovary syndrome: Current status and future perspective. Front Biosci (Elite Ed). 6:104–119. 2014.PubMed/NCBI
28	Xia Y, Zhao P, Huang H, Xie Y, Lu R and Li D: Cryptotanshinone reverses reproductive disturbances in rats with dehydroepiandrosterone-induced polycystic ovary syndrome. Am J Transl Res. 9:2447–2456. 2017.PubMed/NCBI
29	Rosenfield RL and Ehrmann DA: The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 37:467–520. 2016. View Article : Google Scholar : PubMed/NCBI
30	Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN and Blackard WG: A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 72:83–89. 1991. View Article : Google Scholar : PubMed/NCBI
31	Shorakae S, Ranasinha S, Abell S, Lambert G, Lambert E, de Courten B and Teede H: Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS. Clin Endocrinol (Oxf). 89:628–633. 2018. View Article : Google Scholar : PubMed/NCBI
32	Liu M, Gao J, Zhang Y, Li P, Wang H, Ren X and Li C: Serum levels of TSP-1, NF-κB and TGF-β1 in polycystic ovarian syndrome (PCOS) patients in northern China suggest PCOS is associated with chronic inflammation. Clin Endocrinol (Oxf). 83:913–922. 2015. View Article : Google Scholar : PubMed/NCBI
33	Zhang X, Xue C, Xu Q, Zhang Y, Li H, Li F, Liu Y and Guo C: Caprylic acid suppresses inflammation via TLR4/NF-κB signaling and improves atherosclerosis in ApoE-deficient mice. Nutr Metab (Lond). 16:402019. View Article : Google Scholar : PubMed/NCBI
34	Li G, Wu X, Yang L, He Y, Liu Y, Jin X and Yuan H: TLR4-mediated NF-κB signaling pathway mediates HMGB1-induced pancreatic injury in mice with severe acute pancreatitis. Int J Mol Med. 37:99–107. 2016. View Article : Google Scholar : PubMed/NCBI
35	Osuka K, Watanabe Y, Usuda N, Iwami K, Miyachi S and Takayasu M: Expression of high mobility group B1 and toll-like receptor-nuclear factor κB signaling pathway in chronic subdural hematomas. PLoS One. 15:e02336432020. View Article : Google Scholar : PubMed/NCBI
36	Koc O, Ozdemirici S, Acet M, Soyturk U and Aydin S: Nuclear factor-κB expression in the endometrium of normal and overweight women with polycystic ovary syndrome. J Obstet Gynaecol. 37:924–930. 2017. View Article : Google Scholar : PubMed/NCBI
37	Kim SW, Lim CM, Kim JB, Shin JH, Lee S, Lee M and Lee JK: Extracellular HMGB1 released by NMDA treatment confers neuronal apoptosis via RAGE-p38 MAPK/ERK signaling pathway. Neurotox Res. 20:159–169. 2011. View Article : Google Scholar : PubMed/NCBI